Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesamorelin for NAFLD in HIV
NCT02196831Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2015
- Primary completion
- Jan 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of tesamorelin in non-alcoholic fatty liver disease (NAFLD), Nonalcoholic steatohepatitis (NASH), sponsored by Massachusetts General Hospital. Started Jul 2015; status: completed.
02
Drugs
tesamorelin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02196831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02196831.